Swiss Biosimilar Developer mAbxience Acquires Spanish Biologics CMO GenhelixBy
mAbxience, a Swiss company specializing in biosimilar medicines development and manufacturing, has purchased 100% of the Genhelix biopharmaceutical plant, located in LeÃ³n, Spain for EUR 10 million ($13.6 million). mAbxience is part of the Madrid-based pharmaceutical company, The Chemo Group. Genhelix provides contract services for process development and manufacturing of monoclonal antibodies and other biologics.
mAbxience plans to invest in the plant to raise production capacity and more than triple its current staff. With the incorporation of Genhelix, the Chemo Group is strengthening its global presence in Spain, where it already had commercial offices in Barcelona and Madrid, R&D centers in Azuqueca de Henares and LeÃ³n, and manufacturing plants in AlcalÃ¡ de Henares, Azuqueca de Henares and LeÃ³n. The acquisition of the Genhelix plant represents its first industrial presence in Spain in the area of biosimilar medicines. mAbxience also owns the PharmADN and Sinergium Biotech plants, both located in Buenos Aires, Argentina.
The Chemo Group, to which mAbxience belongs, has been operating for more than 35 years and is part of the Insud Group. It employs more than 5,000 professionals in over 40 countries. It has 10 manufacturing plants, nine specialist R&D centers, 12 commercial offices, and 33 subsidiary pharmaceutical companies.
Source: The Chemo Group